GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
GlycoMimetics, Inc. (GLYC)
Last glycomimetics, inc. earnings: 5/1 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.glycomimetics.com/investor-relations
Company Research
Source: Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, on December 7-10, 2024.ASH Annual Meeting abstracts may be accessed online at www.hematology.org. Details of GlycoMimetics presentations are as follows (all times PT):Publication Number: 733Type: OralTitle: Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 TrialPresenter: Daniel DeAngelo, M.D., Ph.D.Session Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: New Treatment Approaches for AMLSession Date/ Presentation Time: Monday, December 9, 2024, 10:30 AM – 12:00 PMPublication Number: 1503Type:
Show less
Read more
Impact Snapshot
Event Time:
GLYC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLYC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLYC alerts
High impacting GlycoMimetics, Inc. news events
Weekly update
A roundup of the hottest topics
GLYC
News
- Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024PR Newswire
- GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. – GLYCGlobeNewswire
- INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. - GLYCPR Newswire
- GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYCBusiness Wire
GLYC
Earnings
- 8/8/24 - Beat
GLYC
Sec Filings
- 11/12/24 - Form SC
- 11/7/24 - Form DEFA14A
- 11/7/24 - Form 8-K
- GLYC's page on the SEC website